Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Kiora Pharmaceuticals (NASDAQ: KPRX) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 3:20 p.m. ET.

A live webcast will be available on the company's investor relations website ir.kiorapharma.com, with a replay accessible for approximately 90 days.

Key Figures

Conference edition: 36th Annual Presentation date: February 26, 2026 Presentation time: 3:20 p.m. ET +1 more

4 metrics

Conference edition 36th Annual Oppenheimer Healthcare Life Sciences Conference

Presentation date February 26, 2026 Scheduled conference presentation date

Presentation time 3:20 p.m. ET Scheduled time for Kiora’s presentation

Webcast replay window 90 days Duration replay will be available on IR website

Market Reality Check

Price: $2.09 Vol: Volume 23,007 vs 20-day a...

low vol

$2.09 Last Close

Volume Volume 23,007 vs 20-day average 84,955 (relative volume 0.27), indicating muted interest ahead of the conference. low

Technical Price 2.09 is trading below the 200-day MA of 2.58, and about 50% under the 52-week high.

Peers on Argus

Momentum scanner shows mixed moves among biotech peers, with names like APRE and...

1 Up 2 Down

Momentum scanner shows mixed moves among biotech peers, with names like APRE and AEON down and BOLT up, and sector commentary noting broader dynamics (median move -4.0%). KPRX’s modest gain of 3.47% came against this mixed sector backdrop.

Historical Context

5 past events · Latest: Jan 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 27	Advisory board addition	Positive	-0.5%	Retinal specialist joined Scientific Advisory Board to guide retinal strategy.
Dec 01	Patent and trial update	Positive	-2.5%	New U.S. patent on KIO-100 formulations and active Phase 2 KLARITY trial.
Nov 07	Earnings and pipeline	Positive	+0.4%	Q3 2025 results, cash position, and progress in two Phase 2 retinal trials.
Oct 30	Consortium collaboration	Positive	+0.8%	Joined RARE-X Vision Consortium to support rare ocular disorder research.
Oct 15	Conference participation	Neutral	-0.7%	Participation in ophthalmology-focused investor and industry events.

Pattern Detected

Recent positive corporate and pipeline updates have not consistently driven upside, with several constructive announcements followed by flat or negative 24h moves.

Recent Company History

Over the past several months, Kiora reported multiple developments, including joining the RARE-X Vision Consortium on Oct 30, 2025 and appointing retinal expert Dr. Taiji Sakamoto to its Scientific Advisory Board on Jan 27, 2026. It advanced retinal programs with two ongoing Phase 2 trials and highlighted cash runway into late 2027 in Q3 2025 results. A U.S. patent on KIO-100 formulations and ongoing KLARITY Phase 2 enrollment were also noted. Against this backdrop, the new conference participation fits a pattern of ongoing investor and scientific outreach.

Market Pulse Summary

This announcement signals continued investor-relations activity, with Kiora presenting at a major he...

Analysis

This announcement signals continued investor-relations activity, with Kiora presenting at a major healthcare conference on February 26, 2026 and offering a webcast replay for 90 days. In context of recent updates on Phase 2 retinal trials, patents, and collaboration initiatives, the event gives management another platform to discuss strategy and progress. Investors may watch for any new qualitative commentary on development timelines, partnering discussions, or cash runway beyond late 2027 in the accompanying presentation materials.

AI-generated analysis. Not financial advice.

Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 3:20 p.m. ET.

A live webcast will be available on Kiora's investor relations website, ir.kiorapharma.com, on the IR homepage and under the News & Events section. A replay of the webcast will be available for approximately 90 days.

About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH). KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration.

In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Contacts:
Investors
investors@kiorapharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/284505

FAQ

When will Kiora Pharmaceuticals (KPRX) present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference?

Kiora will present on Thursday, February 26, 2026 at 3:20 p.m. ET. According to the company, the presentation is part of the conference program and will be available via live webcast on the investor relations site.

How can investors watch Kiora Pharmaceuticals (KPRX) presentation on February 26, 2026?

Investors can watch via a live webcast on ir.kiorapharma.com. According to the company, the webcast is accessible from the IR homepage under News & Events and will stream live at the scheduled time.

Will there be a replay of Kiora Pharmaceuticals (KPRX) Oppenheimer conference presentation and for how long?

Yes, a replay will be available for approximately 90 days after the live event. According to the company, the replay will be posted on the investor relations site for on‑demand viewing during that period.

What time is Kiora Pharmaceuticals (KPRX) scheduled to present at the Oppenheimer conference in ET?

Kiora is scheduled to present at 3:20 p.m. ET on February 26, 2026. According to the company, attendees and investors can join the live webcast at that exact time via the IR website.

Where on Kiora Pharmaceuticals' website will the Oppenheimer conference webcast be posted?

The webcast will be posted on the company's investor relations site at ir.kiorapharma.com. According to the company, it will appear on the IR homepage and under the News & Events section for live and replay access.